We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Suggests Two Types of Bioequivalence Studies for Fidaxomicin Generics
FDA Suggests Two Types of Bioequivalence Studies for Fidaxomicin Generics
Drugmakers seeking approval of fidaxomicin generics to treat Clostridium difficile-associated diarrhea have two options for demonstrating bioequivalence, the FDA said.